Trial Profile
A retrospective study of Pembrolizumab evaluating risk factors of Immune-Related Adverse Events
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Jul 2018
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Malignant melanoma; Solid tumours
- Focus Adverse reactions
- 13 Jul 2018 New trial record
- 16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism